Global Medical Marijuana Market Set To Grow To $32bn By 2022

13 August 2018
Pharma

Visiongain has launched a new pharma report Global Medical Marijuana Market 2017-2027: Chronic Pain, Arthritis, Migraine, Cancer, National Markets, Patent Analysis, Leading Companies

Scientific studies of the extract of marijuana, called cannabinoids, have led to two FDA-approved medications that contain cannabinoid chemicals in pill form. Currently, the two main extract from the marijuana plant that are being used for medical treatments are THC and CBD. THC increases appetite and reduces nausea. THC also decrease pain, inflammation, and muscle control problems. CBD is useful in reducing pain and inflammation, controlling epileptic seizures, muscle spasms caused by multiple sclerosis, nausea, poor appetite, weight loss, crohn’s diseases and possibly treating mental illness and addictions.

The lead analyst of the report commented “Medical Marijuana is one the most promising method to treat various kinds of cancer. Moreover, scientists are doing constant research to make medical marijuana more effective. Hence, increasing research in the improvement of medical marijuana and constant development to find new treatment of cancer is one of the main factors driving the growth of this market.

The growing number of states legalizing medical marijuana and increasing demand for cannabis in medical applications are some of the pivotal factors that are expected to propel the demand for medical marijuana over the coming years.”

Leading companies featured in the report include Cara Therapeutics, Inc., Cannabis Sativa, Inc., CannaGrow Holdings, Inc., Aphios Corporation, United Cannabis Corporation, Growblox Sciences, Inc., GreenGro Technologies, Inc., GW Pharmaceutical, PLC., International Consolidated Companies, Inc., Lexaria Biosciences Corp.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

Read

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

Read

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

Read

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever